CG>TG mutation frequency as negative predictor of homologous recombination deficiency in ovarian and breast cancer
Abstract Homologous recombination deficiency (HRD) is a predictive biomarker for PARP inhibition and platinum-based chemotherapy. While copy number alteration-based scores such as HRDsum = LST + TAI + LOH are included in therapy approvals, single base substitutions (SBS) are underinvestigated as pre...
Saved in:
| Main Authors: | Eva Romanovsky, Michael Menzel, Klaus Kluck, Susanne Beck, Markus Ball, Peter Schirmacher, Daniel Kazdal, Albrecht Stenzinger, Jan Budczies |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Communications Biology |
| Online Access: | https://doi.org/10.1038/s42003-025-08529-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The impact of homologous recombination deficiency on the prognosis of epithelial ovarian cancer
by: Haiqi Su, et al.
Published: (2025-01-01) -
Whole exome sequencing-based homologous recombination deficiency test for epithelial ovarian cancer
by: Ying-Cheng Chiang, et al.
Published: (2025-01-01) -
Analysis of homologous recombination deficiency in prostate cancer
by: A. G. Iyevleva, et al.
Published: (2025-03-01) -
Leveraging homologous recombination repair deficiency in sarcoma
by: Dea Slade, et al.
Published: (2023-03-01) -
Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO)
by: Raphaël Leman, et al.
Published: (2025-07-01)